Antibiotic consideration in bacterial vaginosis

Current Infectious Disease Reports

Volumn 11, Issue 6, 2009, Pages 471-475

  Sobel, Jack D ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; METRONIDAZOLE; SECNIDAZOLE; TINIDAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BACTERIAL TRANSMISSION; BEDTIME DOSAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; GARDNERELLA VAGINALIS; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA HOMINIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINITIS;

EID: 70449484471     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0068-5     Document Type: Review

References (38)

1. J.D. Sobel 2000 Bacterial vaginosis Annu Rev Med 51 349 356 10.1146/annurev.med.51.1.349 1:CAS:528:DC%2BD3cXisVeltro%3D 10774469 (Pubitemid 30216042)
2. E.H. Koumans M. Sternberg C. Bruce, et al. 2007 The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health Sex Transm Dis 34 864 869 10.1097/OLQ.0b013e318074e565 17621244 (Pubitemid 350287499)
3. D.N. Fredricks T.L. Fiedler J.M. Marrazzo 2005 Molecular identification of bacteria associated with bacterial vaginosis N Engl J Med 353 1899 1911 10.1056/NEJMoa043802 1:CAS:528:DC%2BD2MXhtF2rsL%2FL 16267321 (Pubitemid 41565955)
4. M.J. Ferris A. Masztal K.E. Aldridge, et al. 2004 Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis BMC Infect Dis 13 4 5
5. R. Verhelst H. Verstraelen G. Claeys, et al. 2004 Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis BMC Microbiol 4 16 10.1186/1471-2180-4-16 15102329 (Pubitemid 38767490)
6. R. Amsel P.A. Totten C.A. Spiegel, et al. 1983 Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations Am J Med 74 14 22 10.1016/0002-9343(83)91112-9 1:STN:280:DyaL3s%2FpslGltw%3D%3D 6600371 (Pubitemid 13221599)
7. P. Piot E. Van Dyck P. Godts J. Vanderheyden 1983 A placebo-controlled, double-blind comparison of tinidazole and triple sulfonamide cream for the treatment of nonspecific vaginitis Am J Obstet Gynecol 147 85 89 1:STN:280:DyaL3szgsF2ntg%3D%3D 6351619
8. Centers for Disease ControlPrevention K.A. Workowski S.M. Berman 2006 Sexually transmitted diseases treatment guidelines, 2006 MMWR Recomm Rep 55RR-11 1 94
9. O.O. Oduyebo R.I. Anorlu F.T. Ogunsola 2009 The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women Cochrane Database Syst Rev 8 CD006055
10. W.L. Greaves J. Chungafung B. Morris, et al. 1988 Clindamycin versus metronidazole in the treatment of bacterial vaginosis Obstet Gynecol 72 799 802 1:STN:280:DyaL1M%2FhsFGnsA%3D%3D 3050654
11. C.S. Bradshaw A.N. Morton J. Hocking, et al. 2006 High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence J Infect Dis 193 1478 1486 10.1086/503780 16652274 (Pubitemid 43794575)
12. P. Hay 2000 Recurrent bacterial vaginosis Curr Infect Dis Rep 2 506 512 10.1007/s11908-000-0053-5 11095900
13. A. Senok H. Verstraebrn M. Temmerman G. Botta 2006 Probiotics for the treatment of bacterial vaginosis Cochrane Database Syst Rev 4 CD006289
14. K.C. Lamp C.D. Freeman N.E. Klutman M.K. Lacy 1999 Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials Clin Pharmacokinet 36 353 373 10.2165/00003088-199936050-00004 1:CAS:528:DyaK1MXkt1Cls7k%3D 10384859 (Pubitemid 29261511)
15. B. Davis D.D. Glover B. Larsen 1984 Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography Am J Obstet Gynecol 149 802 803 1:CAS:528:DyaL2cXmt1Wqt70%3D 6465238
16. B. Fredricsson B. Hagström C.E. Nord A. Rane 1987 Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration Gynecol Obstet Invest 24 200 207 1:STN:280: DyaL1c%2FosVOisw%3D%3D 3692332
17. J. Mattila P.T. Männistö R. Mäntylä, et al. 1983 Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route Antimicrob Agents Chemother 23 721 725 1:CAS:528: DyaL3sXkt1Oru7g%3D 6870221
18. M.M. Alper B.N. Barwin W.M. McLean, et al. 1985 Systemic absorption of metronidazole by the vaginal route Obstet Gynecol 65 781 784 1:STN:280:DyaL2M3hsVOlsQ%3D%3D 4000568
19. R.W. Manthei L.G. Feo J.E. Stambaugh 1969 Identification of the metabolites of metronidazole in the human vagina Wiad Parazytol 15 403 405 1:STN:280:DyaE3c%2FjtVGnsg%3D%3D 5349981
20. B.M. Jones I. Geary A.B. Alawattegama, et al. 1985 In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis J Antimicrob Chemother 16 189 197 10.1093/jac/16.2.189 1:STN:280:DyaL28%2FlvFSrsQ%3D%3D 3905748
21. P. Nagaraja 2008 Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis Indian J Med Microbiol 26 155 157 10.4103/0255-0857.40531 1:STN:280:DC%2BD1c3otlKrug%3D%3D 18445953 (Pubitemid 351652298)
22. C.S. Easmon C.A. Ison C.M. Kaye, et al. 1982 Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis Br J Vener Dis 58 246 249 1:CAS:528:DyaL38XlslCgtbs%3D 6980684
23. A.B. Onderdonk T.J. Louie F.P. Tally J.G. Bartlett 1979 Activity of metronidazole against Escherichia coli in experimental intra-abdominal sepsis J Antimicrob Chemother 5 201 210 10.1093/jac/5.2.201 1:CAS:528:DyaE1MXktFersLw%3D 372171
24. E. De Backer R. Verhelst H. Verstraelen, et al. 2006 Antibiotic susceptibility of Atopobium vaginae BMC Infect Dis 6 51 10.1186/1471-2334-6-51 16542416 (Pubitemid 43786476)
25. De Backer E, Dubreuil L, Brauman M, et al.: In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect 2009 (Epub ahead of print).
26. A. Swidsinski W. Mendling V. Loening-Baucke, et al. 2005 Adherent biofilms in bacterial vaginosis Obstet Gynecol 106 1013 1023 16260520
27. C.S. Bradshaw S.N. Tabrizi C.K. Fairley, et al. 2006 The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy J Infect Dis 194 828 836 10.1086/506621 1:CAS:528:DC%2BD28XhtVamsLfJ 16941351 (Pubitemid 44344132)
28. J.P. Menard F. Fenollar M. Henry, et al. 2008 Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis Clin Infect Dis 47 33 43 10.1086/588661 1:CAS:528:DC%2BD1cXosFejt7w%3D 18513147 (Pubitemid 351920584)
29. M.N. Austin R.H. Beigi L.A. Meyn S.L. Hillier 2005 Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole J Clin Microbiol 43 4492 4497 10.1128/JCM.43.9.4492-4497.2005 1:CAS:528:DC%2BD2MXhtVOrtLvP 16145097 (Pubitemid 41298233)
30. R.H. Beigi M.N. Austin L.A. Meyn, et al. 2004 Antimicrobial resistance associated with the treatment of bacterial vaginosis Am J Obstet Gynecol 191 1124 1129 10.1016/j.ajog.2004.05.033 15507930 (Pubitemid 39421560)
31. C.Y. Liu Y.T. Huang C.H. Liao, et al. 2008 Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems Antimicrob Agents Chemother 52 3161 3168 10.1128/AAC.00355-08 1:CAS:528:DC%2BD1cXhtF2gtrbI 18625771
32. M.M. Theron M.N. Janse Van Rensburg L.J. Chalkley 2004 Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.) J Antimicrob Chemother 54 240 242 10.1093/jac/dkh270 1:CAS:528:DC%2BD2cXltlyjtrs%3D 15150170 (Pubitemid 39028999)
33. S. Puapermpoonsiri K. Watanabe N. Kato K. Ueno 1997 In vitro activities of 10 antimicrobial agents against bacterial vaginosis-associated anaerobic isolates from pregnant Japanese and Thai women Antimicrob Agents Chemother 41 2297 2299 1:CAS:528:DyaK2sXms1Snsbw%3D 9333068 (Pubitemid 27422233)
34. D.G. Ferris M.S. Litaker L. Woodward, et al. 1995 Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream J Fam Pract 41 443 449 1:STN:280: DyaK28%2Fmslalsg%3D%3D 7595261
35. J.D. Sobel D. Ferris J. Schwebke, et al. 2006 Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis Am J Obstet Gynecol 194 1283 1289 10.1016/j.ajog.2005.11.041 1:CAS:528:DC%2BD28XktVGhtLY%3D 16647911
36. Reichman O, Akins R, Sobel JD: Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009 (Epub ahead of print).
37. S. Sanchez P.J. Garcia K.K. Thomas, et al. 2004 Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial Am J Obstet Gynecol 191 1898 1906 10.1016/j.ajog.2004.06.089 1:CAS:528:DC%2BD2cXhtVKltr%2FK 15592270 (Pubitemid 39601492)
38. B.M. Jones I. Geary M.E. Lee B.I. Duerden 1989 Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections Antimicrob Agents Chemother 33 970 972 1:CAS:528:DyaL1MXkslCltL8%3D 2764547